𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy

✍ Scribed by Seung Tae Kim; Jeeyun Lee; Jeong-hoon Kim; Young-Woong Won; Jong-Mu Sun; Jina Yun; Yeon Hee Park; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
186 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase 1 trial of everolimus and gefitini
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer
✍ Daniel T. Milton; Gregory J. Riely; Christopher G. Azzoli; Jorge E. Gomez; Rober πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 123 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Preclinical studies have demonstrated that the inhibition of the PI3K/Akt/mTOR pathway restores gefitinib sensitivity in resistant cancer cell lines. A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dos

Temporal trends and predictors of periop
Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer
✍ Jue Wang; Yong Fang Kuo; Jean Freeman; Avi B. Markowitz; James S. Goodwin πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 245 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The authors assessed patterns of perioperative chemotherapy use in elderly patients with resected stage I, II, or IIIA nonsmall cell lung cancer (NSCLC) from 1992 to 2002. ## METHODS. By using data from the Surveillance, Epidemiology, and End Results Program, 11,807 pa

Second-line, low-dose, weekly paclitaxel
Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel
✍ Mark A. Socinski; Michael J. Schell; Kamal Bakri; Amy Peterman; Ji-Hyun Lee; Pau πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Second‐line chemotherapy with docetaxel improves survival and quality of life (QoL) in patients with nonsmall cell lung carcinoma (NSCLC) who fail first‐line platinum‐based regimens. The authors sought to determine the activity of second‐line, low‐dose, weekly paclitaxel